Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-BC8 + Bu/Cy + BMT for AML
NCT00002554Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 1993
- Primary completion
- Dec 1999
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of apamistamab in acute myeloid leukemia (AML) (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Overall Survival, Disease-Free Survival and 1 more. Started Nov 1993; status: completed.
02
Drugs
apamistamab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00002554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002554.